Graphical approaches to the analysis of safety data from clinical trials

Pharmaceutical Statistics

Volumn 7, Issue 1, 2008, Pages 20-35

  Amit, Ohad ^a   Heiberger, Richard M ^b   Lane, Peter W ^c  

^a GLAXOSMITHKLINE   (United States)

^b TEMPLE UNIVERSITY   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Adverse experience; Boxplot; Dotplot; Graphics; Hepatotoxicity; QT interval; Trellis display

Indexed keywords

DRUG; PLACEBO;

ANALYTICAL ERROR; ARTICLE; BIOSTATISTICS; CLINICAL TRIAL; DATA ANALYSIS; DRUG SAFETY; ELECTROCARDIOGRAM; HAZARD ASSESSMENT; HUMAN; INCIDENCE; LABORATORY DIAGNOSIS; LIVER FUNCTION TEST; LIVER TOXICITY; METHODOLOGY; PATIENT SAFETY; QT PROLONGATION; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS;

CLINICAL TRIALS AS TOPIC; COMPUTER GRAPHICS; DATA INTERPRETATION, STATISTICAL; DRUG THERAPY; HEART RATE; HUMANS; INFORMATION DISSEMINATION; LIVER; LIVER FUNCTION TESTS; RESEARCH DESIGN; RISK ASSESSMENT; TIME FACTORS;

EID: 40749105725     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.254     Document Type: Article

References (16)

1. Squassante L, Robinson CN, Palmer RL. Simple graphical methods of displaying multiple clinical results. Pharmaceutical Statistics 2006; 5:51-60.
2. Harrell F. Statistical graphics. School of Medicine, University of Virginia, 2002. http://www.healthsystem.virginia.edu/internet/hes/ biostat/docs/teaching/clinicians/graphscourse.pdf. (accessed 24 March 2006).
3. Chuang-Stein C, Le V, Chen W. Recent advances in the analysis and presentation of safety data. Drug Information Journal 2001; 35:377-397.
4. Wainer H. Graphic Discovery, Chapter 4. Princeton University Press: Princeton NJ, 2005.
5. Tufte WER. The Visual Display of Information. Graphics Press: Cheshire CT, 1983.
6. Cleveland WS. The Elements of Graphing Data. Wadsworth: Monterey CA, 1985.
7. ICH. The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs E14. http://www.ich.org/LOB/media/MEDIA1476.pdf 2005 (accessed 24 March 2006).
8. Hoaglin DC, Mosteller F, Tukey JW (eds). Understanding Robust and Exploratory Data Analysis. Wiley: New York, 1983.
9. Heiberger RM, Holland B. Statistical Analysis and Data Display: an Intermediate Course with Examples in S-Plus, R, and SAS. Springer: New York, 2004. With accompanying online files at http://springeronline.com/0-387-40270-5. Graphical approaches to the analysis of safety data 35
10. Agresti A. Categorical Data Analysis. Wiley: New York, 1990.
11. ICH. Statistical Principles for Clinical Trials E9. http://www.ich.org/ LOB/media/MEDIA485.pdf 1998 (accessed 24 March 2006).
12. ICH (International Conference on Harmonisation) Structure and Content of Clinical Study Reports E3. http://www.ich.org/LOB/media/MEDIA479.pdf 1995 (accessed 24 March 2006).
13. O'Neill RT. Biostatistical considerations in pharmacovigilance and pharmacoepidemiology: linking quantitative risk assessment in pre-market licensure application safety data, post-market alert reports and formal epidemiological studies. Statistics in Medicine 1998; 17:1851-1858.
14. Gait JE, Smith S, Brown SL. Evaluation of safety data from controlled clinical trials: the clinical principles explained. DIA Journal 2000; 34:273-287.
15. Ioannidis JPA, Lau J. Improving safety reporting from randomised trials. Drug Safety 2002; 25: 77-84.
16. Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. The Lancet 2002; 359: 1686-1689.